Endocrine Abstracts

Background and Aim: Coffee is consumed worldwide and have been an important aspect of societal norms and cultural traditions for centuries. The health effects of routine caffeine consumption and their potential function as modifiable risk factors for cardiovascular disease have recently been the suggested by many studies. The aim of this study is to evaluate the daily caffeine consumption in obese patients and its clinical and metabolic effects.

Methods: This is a cross-sectional study conducted in 70 obese patients. Patients’ demographic and anthropometric characteristics, obesity related complications and biological parameters were collected. Insulin resistance was estimated by HOMA-IR index. Metabolic syndrome was defined according to the International Diabetes Federation criteria (2009). Caffein daily consumption was evaluated depending on the average quantity of coffee and the type of coffee consumed according to the international caffein organization¹. Low caffeine consumption was defined by an average consumption of less than 200 mg per day, a consumption of caffeine between 200 and 400 mg per day defined a moderate consumption and high caffeine consumption was defined as a daily intake of more than 400 mg. In this study we combined moderate and high caffeine consumption to improve precision of estimates.

Results: Mean age was 50.91±11.5years with female predominance(90%). Mean Body mass index (BMI)was 39.42±6.47 kg/m², mean waist circumference was 118.95±11.04 cm. Of the study population, 22.9% of patients had class 1 obesity,38.6% of patients had class 2 obesity and 37.1% had morbid obesity. Insulin resistance was noted in 87.5% of cases and more than half of patients had metabolic syndrome (65.7%). Coffee was consumed on a daily average of 193±73.42 ml, which was equivalent to an average of 133.96±85.95 mg of caffeine per day. Caffeine intake was minimal, moderate, and high in 81.2%, 17.1% and 1.4% of cases, respectively. Patients with minimal caffeine intake had a significantly higher prevalence of metabolic syndrome compared to patients with moderate to high caffeine intake (61.4% vs 4.3%; P=0.001). Prevalence of nonalcoholic fatty liver disease and insulin resistance did not statistically differ between the two groups. Systolic and diastolic blood pressure values, total cholesterol, triglyceride, HDL-c and LDL-c levels did not statistically differ between the two groups.

Conclusion: Moderate to high habitual consumption of caffeinated beverages is safe across a broad range of cardiovascular conditions. Our findings support the hypothesis on the possible health benefits of caffein consumption particularly on metabolic syndrome, yet further research on large-scale studies is needed.

Reference: 1. International Coffee Organization - Caféine [Internet]. [cité 2022 déc 6]; Available from: https://www.ico.org/fr/caffeine_f.asp#contents